ABSTRACT

Introduction

The development of companion diagnostics (CDx) will increase efficacy and cost-benefit markedly, compared to the currently prevailing trial-and-error approach for treatment. Recent improvements in high-throughput protein technology have resulted in large amounts of predictive biomarkers that are potentially useful components of future CDx assays. Current high multiplex protein arrays are suitable for discovery-based approaches, while low-density and more simple arrays are suitable for use in point-of-care facilities.

Area covered

This review discusses the technical platforms available for protein array focused CDx, explains the technical details of the platforms and provide examples of clinical use, ranging from multiplex arrays to low-density clinically applicable arrays. We thereafter highlight recent predictive biomarkers within different disease areas, such as oncology and autoimmune diseases. Lastly, we discuss some of the challenges connected to the implementation of CDx assays as point-of-care tests.

Expert opinion

Recent advances in the field of protein arrays have enabled high-density arrays permitting large biomarker discovery studies, which are beneficial for future CDx assays. The density of protein arrays range from a single protein to proteome-wide arrays, allowing the discovery of protein signatures that may correlate with drug response. Protein arrays will undoubtedly play a key role in future CDx assays.

中文翻译：

---

精准医学中基于蛋白质阵列的伴随诊断

摘要

介绍

与目前流行的试错法治疗相比，伴随诊断 (CDx) 的发展将显着提高疗效和成本效益。高通量蛋白质技术的最新改进产生了大量预测性生物标志物，这些生物标志物是未来 CDx 检测的潜在有用组成部分。当前的高多重蛋白质阵列适用于基于发现的方法，而低密度和更简单的阵列适用于即时护理设施。

覆盖区域

本综述讨论了可用于蛋白质阵列聚焦 CDx 的技术平台，解释了平台的技术细节并提供了临床使用示例，范围从多重阵列到低密度临床适用阵列。此后，我们重点介绍了不同疾病领域（例如肿瘤学和自身免疫性疾病）中最近的预测性生物标志物。最后，我们讨论了一些与实施 CDx 检测作为即时检验相关的挑战。

专家意见

蛋白质阵列领域的最新进展使高密度阵列成为可能，允许大型生物标志物发现研究，这有利于未来的 CDx 检测。蛋白质阵列的密度范围从单一蛋白质到蛋白质组范围的阵列，允许发现可能与药物反应相关的蛋白质特征。蛋白质阵列无疑将在未来的 CDx 检测中发挥关键作用。